Title	Acquisition of monosomy 7 and a RUNX1 mutation in Pearson syndrome
Author(s)	Nishimura, Akira; Hirabayashi, Shinsuke; Hasegawa, Daisuke; Yoshida, Kenichi; Shiraishi, Yuichi; Ashiarai, Miho; Hosoya, Yosuke; Fujiwara, Tooru; Harigae, Hideo; Miyano, Satoru; Ogawa, Seishi; Manabe, Atsushi
Citation	Pediatric blood & cancer, 68(2), e28799 https://doi.org/10.1002/pbc.28799
Issue Date	2021-02
Doc URL	http://hdl.handle.net/2115/84042
Rights	This is the peer reviewed version of the following article: Nishimura, A, Hirabayashi, S, Hasegawa, D, et al. Acquisition of monosomy 7 and a RUNX1 mutation in Pearson syndrome. <i>Pediatr Blood Cancer</i> . 2021; 68:e28799, which has been published in final form at https://doi.org/10.1002/pbc.28799 . This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Use of Self-Archived Versions
Type	article (author version)
File Information	Pediatr Blood Cancer_68_e28799.pdf

[Instructions for use](#)

Acquisition of monosomy 7 and a *RUNX1* mutation in Pearson syndrome

Akira Nishimura^{1,2}, Shinsuke Hirabayashi^{1,3}, Daisuke Hasegawa¹, Kenichi Yoshida⁴,
Yuichi Shiraishi⁵, Miho Ashiarai¹, Yosuke Hosoya¹, Tohru Fujiwara⁶, Hideo Harigae⁶,
Satoru Miyano⁵, Seishi Ogawa^{4,7,8} and Atsushi Manabe^{1,3}

¹Department of Pediatrics, St. Luke's International Hospital, Tokyo, Japan; ²Department of Pediatrics and Developmental Biology, Tokyo Medical and Dental University, Tokyo, Japan; ³Department of Pediatrics, Hokkaido University Graduate School of Medicine, Sapporo, Japan; ⁴Department of Pathology and Tumor Biology, Graduate School of Medicine, Kyoto University, Kyoto, Japan; ⁵Laboratory of DNA Information Analysis, Human Genome Center, Institute of Medical Science, University of Tokyo, Tokyo, Japan; ⁶Department of Hematology and Rheumatology, Tohoku University Graduate School, Sendai, Japan; ⁷Institute for the Advanced Study of Human Biology (WPI ASHBI), Kyoto University, Kyoto, Japan; ⁸Department of Medicine, Center for Hematology and Regenerative Medicine, Karolinska Institute, Stockholm, Sweden

Correspondence to:

Shinsuke Hirabayashi, MD
Department of Pediatrics,
Hokkaido University Graduate School of Medicine, Sapporo, Japan
Kita 15, Nishi 7, Kita-ku, Sapporo, 060-8638, Japan
Phone:+81-11-706-5954 Fax:+81-11-706-7898 E-mail: hirabayashi-slh@umin.ac.jp

Word count: abstract: 97; Manuscript: 1,230; Reference 25; Table: 1; Figure 1.

Keywords: Monosomy 7, *RUNX1*, Pearson syndrome

Running head: Monosomy 7 and *RUNX1* mutation in PS

Abbreviations	
BM	bone marrow
HSCT	hematopoietic stem cell transplantation
IBMFS	inherited bone marrow failure syndrome
MDS	myelodysplastic syndrome
mtDNA	mitochondrial DNA
PS	Pearson syndrome
WES	whole exome sequencing

ABSTRACT

Pearson syndrome (PS) is a very rare and often fatal multisystem disease caused by deletions in mitochondrial DNA that result in sideroblastic anemia, vacuolization of marrow precursors, and pancreatic dysfunction. Spontaneous recovery from anemia is often observed within several years of diagnosis. We present the case of a 4-month-old male diagnosed with PS who experienced prolonged severe pancytopenia preceding the emergence of monosomy 7. Whole-exome sequencing identified two somatic mutations including *RUNX1* p.S100F that was previously reported as associated with myeloid malignancies. The molecular defects associated with PS may have the potential to progress to advanced MDS.

44 INTRODUCTION

45 Pearson syndrome (PS) is a multi-organ system disorder characterized by refractory
46 sideroblastic anemia with vacuolization of bone marrow (BM) precursors, lactic
47 acidosis and exocrine pancreatic dysfunction that result from the deletion of
48 mitochondrial DNA (mtDNA) sequences. Pancreatic dysfunction frequently
49 accompanies PS but it is not critical for the diagnosis.^{1,2} The incidence of PS is very
50 low, at approximately one case per million individuals.³ PS is one of the disorders to
51 be considered in the differential diagnosis of hypocellular BM in young children.^{4,5} It is
52 not clear whether PS is associated with malignant transformation; the long-term
53 prognosis of PS is generally poor, as children often succumb to fatal lactic acidosis.⁶

54 Monosomy 7 is a common cytogenetic abnormality identified in inherited BM failure
55 syndromes (IBMFS) and pediatric myelodysplastic syndrome (MDS).⁷ The basic
56 mechanisms underlying the acquisition of monosomy 7, including haplo-insufficiency
57 and related somatic events, have been explored previously.⁸ Here we describe a case
58 of a patient diagnosed with PS who experienced prolonged and severe pancytopenia
59 followed by the emergence of monosomy 7 and a somatic mutation in *RUNX1*
60 underwent hematopoietic stem cell transplantation (HSCT).

61

62 **METHODS**

63 Written informed consent from the guardians of the patient was obtained for sample
64 storage and analyses. The analyses were conducted in accordance with the
65 Declaration of Helsinki. DNA from BM cells obtained from the patient at diagnosis and
66 again upon development of pancytopenia were subjected to whole-exome sequencing
67 (WES); DNA from buccal cells was used as a germline control. Whole-exome capture
68 was performed using SureSelect Human All Exon Kit V6 (Agilent Technology, Santa
69 Clara, CA, USA). Captured targets were subjected to sequencing using a HiSeq 2000
70 (Illumina, San Diego, CA, USA). With mean depths of 114-143x, sequence alignments
71 and mutation identifications were performed using our in-house Genomon program,
72 as previously described.⁹ Candidate mutations were identified with the following filters:
73 (i) P -value $< 10^{-1.3}$ (by Fisher's test); (ii) EB call (Empirical Bayesian mutation calling)¹⁰
74 P -value $< 10^{-4}$; (iii) variant allele frequency in normal sample < 0.02 . Copy number
75 analysis was performed using in-house program known as CNACS¹¹
76 (https://github.com/papaemmelab/toil_cnacs). Frequency of deletion in mtDNA was

calculated as mean depth of mtDNA with deletion detected (MT:8,469–13,446) divided by those without (MT:1–8,468).

RESULTS AND DISCUSSION

A 4-month-old boy was admitted for treatment of respiratory syncytial virus infection and mild pancytopenia. There was no past medical history or any notable family history. Examination of the BM was notable for vacuolated myeloid and erythroid precursors with ring sideroblasts. Chromosomal analysis revealed 46,XY in 20 out of 20 metaphase spreads. Blood levels of lactic acid were elevated; as such, genetic testing was performed. A large deletion of mtDNA was detected, which indicates a diagnosis of PS. The deleted mtDNA allele was detected at a frequency 81% in BM as a consequence of heteroplasmy that was identified by WES with off-target sequencing reads on mtDNA (Figure 1a). No somatic mutations were detected in BM cells at diagnosis.

The patient began a series of regular red blood cell transfusions to treat his anemia. At the age of 22 months, BM examination revealed significant hemophagocytosis after a respiratory tract infection that resolved in response to prednisolone. Profound

94 thrombocytopenia and neutropenia emerged at the age of 30 months. Platelets counts
95 were fluctuating with regular transfusion. Absolute neutrophil counts was stable
96 around 300 / μ L. BM examination revealed hypo-cellular marrow with 2 % of
97 myeloblasts and minimal dysplasia. A repeat chromosomal analysis revealed a 45,XY,
98 -7 [12]/ 45, idem, t(4;21)(p11;q22) [4]/ 46, XY [4] aberration; monosomy 7 was also in
99 38% of the cells by fluorescent *in situ* hybridization and WES (Figure 1b). Furthermore,
100 WES revealed two somatic mutations of *RUNX1* and *LINGO4* in addition to monosomy
101 7 (Table 1). *RUNX1* p.S100F mutation was previously reported in myeloid
102 malignancies.¹² The frequency of mtDNA deletion was 78%. The patient received an
103 unrelated cord blood transplantation at the age of 42 months to treat prolonged
104 pancytopenia. The conditioning regimen included anti-thymocyte globulin, fludarabine,
105 and melphalan from HLA fully matched (8/8) unrelated cord blood. Lactic acidosis
106 deteriorated with infusion reaction by anti-thymocyte globulin. Neutrophil engraftment
107 was obtained on day 20. Acute GVHD of skin (stage 3) and liver (stage 1) were
108 resolved with prednisolone. He was discharged on day 66. His hematological status
109 and acid-base balance are stable 20 months after HSCT.

110 The proportion of deleted mtDNA in hematopoietic cells of patients diagnosed with
111 PS varies due to heteroplasmy; the severity of hematologic manifestations is directly
112 related to this phenomenon. Cytopenia associated with PS may resolve
113 spontaneously with a decreasing frequency of mitochondria with deleted mtDNA.^{13,14}
114 Our patient did not experience any resolution of his anemia; the ratio of deleted to
115 intact mtDNA did not change over time as assessed by WES. In addition to persistent
116 BM failure, monosomy 7 appeared two years after initial diagnosis. PS is important as
117 a differential diagnosis of IBMFS, however it is considered to be a non-hematological
118 disorder. Actually, development of cytogenetic abnormalities was previously reported
119 in three cases of PS; all cases had chromosome 7 related abnormalities. The clinical
120 course varied from transient abnormalities to progression AML.^{4, 15,16}

121 Monosomy 7 occurs during the clonal evolution to MDS/leukemia in a variety of
122 IBMFSs.⁷ MDS with monosomy 7 in children has been associated with a high risk of
123 disease progression.¹⁷ Among those cohorts, patients with germline *SAMD9/9L*
124 mutations also frequently developed monosomy 7 as a consequence of an adaptation-
125 by-aneuploidy mechanism.¹⁸ *SAMD9/9L* locate on chromosome 7, and their mutations
126 have growth-restricting activity. WES confirmed that our patient harbored no known

127 germline abnormalities including *SAMD9/9L*, *GATA2* and *FANC* genes that would
128 suggest a predisposition to MDS. Acquisition and selection of monosomy 7 clones
129 may be caused with a similar mechanism in patients with BM failure⁷ where the
130 hematopoietic milieu is exposed to cytopenia-induced stress. Of note, our patient did
131 not undergo treatment with G-CSF, which is known to be associated with the
132 development of monosomy 7 in patients with BM failure.¹⁹

133 Acquisition of additional genetic abnormalities predicts disease progression in adult
134 MDS.²⁰ One study showed that MDS in children was often associated with Ras/MAPK
135 pathway mutations; by contrast, children with germline *SAMD9/9L* mutations rarely
136 acquired additional gene or chromosomal alterations.²¹ Monosomy 7 itself results in
137 haplo-insufficiency of tumor suppressor genes on chromosome 7, which could
138 cooperate with other driver events in modulating the pathogenesis of myeloid
139 malignancies. For example, loss of *EZH2* (located on 7q36) has been shown to
140 interact with *RUNX1* mutations and to generate myeloid tumors in mice.²² Somatic
141 mutations in *RUNX1* are reported frequently in association with childhood MDS with
142 monosomy 7.²³ In IBMFSSs, including Fanconi anemia and severe congenital
143 neutropenia, the combination of *RUNX1* mutations and monosomy 7 also contribute

to myeloid leukemogenesis.^{24,25} Of note, a *RUNX1* mutation that has been associated with myeloid malignancies was also identified in our patient. This clone might have had the potential to progress to advanced MDS.

The cases of two patients with PS who received unrelated HSCT were previously described in the literatures.^{15,16} In one patient, both hematological and non-hematological manifestations resolved in response to this intervention,¹⁶ similar to that observed in our case. PS has features of fatal multisystem dysfunction and spontaneous recovery from anemia within several years of diagnosis. Although HSCT can result in serious complications, it may be a feasible option for patients with severe PS who acquired cytogenetically abnormalities in BM and should be considered in a future prospective clinical trial.

Acknowledgements

This work was supported by the Japan Society for the Promotion of Science (JSPS) through Grants-in-Aid for Scientific Research (KAKENHI), grant number (16K21376 and 18K16128 to S.H, JP26221308 and JP19H05656 to S.O) and also by the Japan

Agency for Medical Research and Development (AMED); the Project for Development
of Innovative Research on Cancer Therapeutics (JP 20cm0106501h0005 to S. O.).

Authorship Contributions

Conception and design: A.N, S.H., D.H., and A.M. Data analysis and interpretation: all
authors. Manuscript writing and final approval: all authors.

Disclosure of Conflicts of Interest

All authors declare that there are no conflicts of interest.

References

1. Pearson HA, Lobel JS, Kocoshis SA, et al. A new syndrome of refractory sideroblastic anemia with vacuolization of marrow precursors and exocrine pancreatic dysfunction. *J Pediatr.* 1979;95(6):976-984.
2. Rotig A, Colonna M, Bonnefont JP, et al. Mitochondrial DNA deletion in Pearson's marrow/pancreas syndrome. *Lancet.* 1989;1(8643):902-903.
3. Farruggia P, Di Cataldo A, Pinto RM, et al. Pearson Syndrome: A Retrospective Cohort Study from the Marrow Failure Study Group of A.I.E.O.P. (Associazione Italiana Emato-Oncologia Pediatrica). *JIMD Rep.* 2016;26:37-43.
4. Gagne KE, Ghazvinian R, Yuan D, et al. Pearson marrow pancreas syndrome in patients suspected to have Diamond-Blackfan anemia. *Blood.* 2014;124(3):437-440.
5. Niemeyer CM, Baumann I. Classification of childhood aplastic anemia and myelodysplastic syndrome. *Hematology / the Education Program of the American Society of Hematology American Society of Hematology Education Program.* 2011;2011:84-89.
6. Yoshimi A, Grünert SC, Cario H, et al. Hematological presentation and change in clinical phenotype during follow-up in Pearson syndrome. *Blood.* 2019;134 (Supplement_1):3746.
7. Wlodarski MW, Sahoo SS, Niemeyer CM. Monosomy 7 in Pediatric Myelodysplastic Syndromes.

203 *Hematol Oncol Clin North Am.* 2018;32(4):729-743.

204 8. Inaba T, Honda H, Matsui H. The enigma of monosomy 7. *Blood.* 2018;131(26):2891-2898.

205 9. Yokoyama A, Kakiuchi N, Yoshizato T, et al. Age-related remodelling of oesophageal epithelia by

206 mutated cancer drivers. *Nature.* 2019;565(7739):312-317.

207 10. Shiraishi Y, Sato Y, Chiba K, et al. An empirical Bayesian framework for somatic mutation detection

208 from cancer genome sequencing data. *Nucleic Acids Res.* 2013;41(7):e89.

209 11. Yoshizato T, Nannya Y, Atsuta Y, et al. Genetic abnormalities in myelodysplasia and secondary

210 acute myeloid leukemia: impact on outcome of stem cell transplantation. *Blood.*

211 2017;129(17):2347-2358.

212 12. Papaemmanuil E, Gerstung M, Bullinger L, et al. Genomic Classification and Prognosis in Acute

213 Myeloid Leukemia. *The New England journal of medicine.* 2016;374(23):2209-2221.

214 13. Muraki K, Nishimura S, Goto Y, Nonaka I, Sakura N, Ueda K. The association between

215 haematological manifestation and mtDNA deletions in Pearson syndrome. *J Inherit Metab Dis.*

216 1997;20(5):697-703.

217 14. Yanagihara I, Inui K, Yanagihara K, et al. Fluorescence in situ hybridization analysis of peripheral

218 blood cells in Pearson marrow-pancreas syndrome. *J Pediatr.* 2001;139(3):452-455.

219 15. Faraci M, Cuzzubbo D, Micalizzi C, et al. Allogeneic bone marrow transplantation for Pearson's

220 syndrome. *Bone Marrow Transplant*. 2007;39(9):563-565.

221 16. Hoyoux C, Dresse MF, Robinet S, et al. Cord blood transplantation in a child with Pearson's disease.

222 *Pediatr Blood Cancer*. 2008;51(4):566.

223 17. Kardos G, Baumann I, Passmore SJ, et al. Refractory anemia in childhood: a retrospective analysis

224 of 67 patients with particular reference to monosomy 7. *Blood*. 2003;102(6):1997-2003.

225 18. Narumi S, Amano N, Ishii T, et al. SAMD9 mutations cause a novel multisystem disorder, MIRAGE

226 syndrome, and are associated with loss of chromosome 7. *Nature genetics*. 2016;48(7):792-797.

227 19. Ohara A, Kojima S, Hamajima N, et al. Myelodysplastic syndrome and acute myelogenous

228 leukemia as a late clonal complication in children with acquired aplastic anemia. *Blood*.

229 1997;90(3):1009-1013.

230 20. Makishima H, Yoshizato T, Yoshida K, et al. Dynamics of clonal evolution in myelodysplastic

231 syndromes. *Nature genetics*. 2017;49(2):204-212.

232 21. Schwartz JR, Ma J, Lamprecht T, et al. The genomic landscape of pediatric myelodysplastic

233 syndromes. *Nat Commun*. 2017;8(1):1557.

234 22. Sashida G, Harada H, Matsui H, et al. Ezh2 loss promotes development of myelodysplastic

235 syndrome but attenuates its predisposition to leukaemic transformation. *Nat Commun*.

236 2014;5:4177.

237 23. Pastor V, Hirabayashi S, Karow A, et al. Mutational landscape in children with myelodysplastic
238 syndromes is distinct from adults: specific somatic drivers and novel germline variants. *Leukemia*.
239 2017;31(3):759-762.

240 24. Quentin S, Cuccuini W, Ceccaldi R, et al. Myelodysplasia and leukemia of Fanconi anemia are
241 associated with a specific pattern of genomic abnormalities that includes cryptic RUNX1/AML1
242 lesions. *Blood*. 2011;117(15):e161-170.

243 25. Skokowa J, Steinemann D, Katsman-Kuipers JE, et al. Cooperativity of RUNX1 and CSF3R
244 mutations in severe congenital neutropenia: a unique pathway in myeloid leukemogenesis. *Blood*.
245 2014;123(14):2229-2237.

246

247

248

249

250

251

252

253

254 **TABLE AND FIGURE LEGENDS**

255

256 **Table 1.**

257 Mutations identified by whole-exome sequencing.

258

259 **Figure 1.**

260 Deletion in mtDNA and monosomy 7 detected by whole-exome sequencing.

261 a) Deletion in mtDNA. Sequencing depth on mtDNA are displayed in gray using IGV
262 for samples at diagnosis and after the development of pancytopenia as well as a
263 control sample. Colored positions mean the positions where alleles different from the
264 reference sequence were called.

265 b) Monosomy 7 after the development of pancytopenia. Total copy number (CN) and
266 allele specific (AS) CN of chromosome 7 are shown for samples at diagnosis and after
267 the development of pancytopenia.

Figure 1

a

b

Table 1. Mutations identified by whole exome sequencing

Chr	Start	End	Ref	Alt	Gene	Exonic function	Amino acid change	VAF_tumor	VAF_normal
21	36259192	36259192	G	A	<i>RUNX1</i>	Missense SNV	NM_001754:exon4:c.C299T:p.S100F	0.086	0
1	151774970	151774970	G	A	<i>LINGO4</i>	Missense SNV	NM_001004432:exon2:c.C211T:p.R71C	0.032	0